Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

Hims & Hers (NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NYSE: NVO) asked the FDA to not allow companies to compound GLP-1 semaglutide. This ...

Hims & Hers Health will join the S&P SmallCap 600 prior to the opening of trading on Wednesday. Hims & Hers will replace Vector Group, which is being acquired by JT Group. Hims & Hers Health Inc ...

Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.

Hims is one of the many platforms that offer telehealth online from licensed providers, with services spanning from skincare and hair loss to anxiety and erectile dysfunction. In this review, we ...

Hims & Hers Health, Inc. HIMS shares rallied 10.1% in the last trading session to close at $19.44. This move can be attributable to notable volume with a higher number of shares being traded than ...

Hims & Hers Health (NYSE:HIMS) saw its shares surge by 7% today after the FDA announced that it would reconsider its decision to limit compounded weight-loss drugs, following a lawsuit from the ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $25.00.